Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04088500 · ClinicalTrials.gov registry record · Phase 2
A Study of Combination Nivolumab and Ipilimumab Retreatment in Patients With Advanced Renal Cell Carcinoma
A Phase 2 study, sponsored by Bristol-Myers Squibb.
- Terminated
- Registry status
- Phase 2
- Development phase
- 5
- Enrollment target
NCT04088500 is a Phase 2 study that was terminated before completion, run by Bristol-Myers Squibb. The registered enrollment target is 5 participants.
The verdict
NCT04088500, a Phase 2 study, was terminated before completion, sponsored by Bristol-Myers Squibb.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 5 participants
- Enrollment target
Study Summary
The purpose of the study is to assess the effectiveness of re-induction with Nivolumab combined with ipilimumab.
Interventions
- BIOLOGICAL Nivolumab
- BIOLOGICAL Ipilimumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2020-09-03 |
| Est. Completion | 2021-11-15 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04088500
The ClinicalTrials.gov registry entry for NCT04088500 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Nivolumab is the first listed.
NCT04088500 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04088500 about?
NCT04088500 is a clinical study titled "A Study of Combination Nivolumab and Ipilimumab Retreatment in Patients With Advanced Renal Cell Carcinoma". The purpose of the study is to assess the effectiveness of re-induction with Nivolumab combined with ipilimumab.
What is the current status of trial NCT04088500?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 5 participants. The study started on 2020-09-03. Estimated completion is 2021-11-15.
What interventions are being tested in trial NCT04088500?
The interventions under investigation include: Nivolumab (BIOLOGICAL), Ipilimumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT04088500?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.